BUZZ-Mustang soars on FDA's orphan drug tag for brain cancer therapy

Reuters
3 hours ago
BUZZ-Mustang soars on FDA's orphan drug tag for brain cancer therapy

** Shares of cancer therapy developer Mustang Bio MBIO.O rise 234% to over 5-month high of $3.97

** Stock set for its best day in over a year, if gains hold

** Co says it received 'orphan drug designation' from the FDA for its experimental cancer therapy, MB-101, to treat astrocytomas and glioblastoma

** The designation gives Mustang incentives like tax credits and seven years of market exclusivity if the product is approved

** Astrocytomas and glioblastoma are brain cancers that develop from star-shaped support cells in the brain, with glioblastoma being the most aggressive form

** MB-101 works by training the body's own immune cells to find and destroy brain cancer cells by targeting a specific protein, IL13Rα2, found on the surface of those tumors

** FDA grants orphan drug status to promote drug development for rare diseases affecting fewer than 200,000 people in the U.S.

** Including session's moves, stock down 55.4% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10